Isovaleric Acidemia Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Globa Isovaleric Acidemia Market  is Segmented By Disease Type (Acute Isovaleric Acidemia, Neonatal Isovaleric Acidemia), By Supplement Type (L-Carnitine, Glycine), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Isovaleric Acidemia Market Overview

Global Isovaleric Acidemia Market is expected to reach at a high CAGR during the forecast period 2023-2030.

The global isovaleric acidemia market experiencing growth in recent years, with various factors influencing its dynamics such as increasing awareness, and others. The isovaleric acidemia also known as isovaleric aciduria, isovaleric acid CoA dehydrogenase deficiency. There is no specific treatment for this disease, but by using supplements such as L-carnitine and glycine, this condition can be managed. Similarly, North America dominates the isovaleric acidemia market, capturing the largest market share owing to the region’s favorable reimbursement policies and advanced healthcare infrastructure.

Moreover, owing to the factors such as increasing awareness, and early detection and diagnosis for better management are expected to drive the global market over the forecast period. However, lack of appropriate treatment options and lack of funding and investments are the factors expected to hamper the market growth. 

Isovaleric Acidemia Market Scope

For more details on this report Request for Sample

Isovaleric Acidemia Market Dynamics

Increasing Awareness is Expected to Drive the Growth of the Market

The increasing awareness is expected to drive the growth of the market over the forecast period. The increasing awareness about isovaleric acidemia among the general public can lead to earlier identification of the condition. The prevalence is very low due to its rarity, the increasing awareness about the condition helps people to better manage in the early stages. This increasing awareness helps to prevent further complications.

Moreover, the increased awareness about this rare type of condition can helps to attract more funding for research into isovaleric acidemia. This can include government grants, donations, and investments from pharmaceutical companies. Increased research funding can accelerate the development of new treatments and therapies for the condition, expanding the market for the development of better products for better treatment or management.

Early Detection and Diagnosis for Better Management is Also Expected to Drive the Growth of the Market

The early detection and diagnosis helps for the better management of isovaleric acidemia, which is expected to drive the market over the forecast period. As awareness about the condition and its potential health implications increases, there is likely to be an increased demand for diagnostic tests, such as newborn screening, genetic testing, and others. This can lead to a larger market for diagnostic laboratories and testing services. Early detection helps to manage the condition in better ways by lifestyle changes like consuming healthy diet and dietary supplements.

Furthermore, early diagnosis and early detection allow for timely medical intervention and management of the disease severity. This can include dietary modifications, medical supplementation, and other treatments aimed at preventing or reducing the severity of metabolic crises and associated symptoms. Early diagnosis can result in a greater number of individuals with this type of disease receiving supportive therapies, such as L-carnitine supplementation and nutritional guidance. This can expand the market for these therapies.

Lack of Appropriate Treatment is Expected to Hamper the Market's Growth

The lack of appropriate treatment for isovaleric acidemia is expected to hamper the market growth over the forecast period. Without effective treatments, patients with this condition are facing complications in treating the condition and their associated complications. The patients who are diagnosed with this disease are managing the condition with a healthy diet and by consuming supplements such as L-carnitine and glycine rather than treating them. 

Additionally, the lack of approved drugs or therapies for isovaleric acidemia can deter pharmaceutical companies and medical device manufacturers from investing in research and development for this condition. The absence of marketable products can lead to a lack of competition and innovation, leading to hampering the growth of the market.

Isovaleric Acidemia Market Segmentation Analysis

The global isovaleric acidemia market is segmented based on disease type, supplement type, distribution channel and region.

The L-Carnitine Segment Accounted for Approximately 43% of the Isovaleric Acidemia Market Share

The L-carnitine segment is expected to hold the largest market share over the forecast period. Isovaleric acidemia, resulting from isovaleryl-coenzyme A dehydrogenase deficiency, is associated with a marked reduction of free carnitine in both plasma and urine. Administration of equimolar amounts of L-carnitine separately with leucine demonstrated that isovaleryl-coenzyme A is removed by supplemental L-carnitine in the form of isovalerylcarnitine. When L-carnitine is given alone, excretion of isovalerylglycine decreases in preference to enhanced excretion of isovalerylcarnitine and hippurate. 

For instance, according to the National Institute of Health (NIH), isovaleric acidemia treatment with L-carnitine alone has proven effective in preventing further hospitalizations in a patient with this type of genetic disorder. 

Moreover, L-carnitine helps transport long-chain fatty acids into the mitochondria, where they can be used as an energy source. In isovaleric acidemia, there is a buildup of isovaleric acid, which can disrupt normal fatty acid metabolism. L-carnitine supplementation can help support this metabolic process by facilitating the transport of fatty acids.  Additionally, L-carnitine can also aid in the removal of toxic metabolites, such as isovalerylcarnitine, which can accumulate in this condition. 

Global Isovaleric Acidemia Market Geographical Share

North America Accounted for Approximately 41% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and Favourable Reimbursement Policies

North America region is expected to hold the largest market share over the forecast period owing to the advanced healthcare infrastructure and favorable reimbursement policies. The region is well-known for its advanced healthcare infrastructure including hospitals with advanced diagnostic features for early diagnosis of the condition, specialty clinics, research academics, and institutes for advanced research. The region has a prevalence of the condition, the patients seek better management. 

For instance, according to the National Organization for Rare Disorders (NORD), Massachusetts, Isovaleric acidemia is a rare disorder that presents either soon after birth or during infancy. It may present up to adolescence. It affects an equal number of males and females. The prevalence of this condition is 1 per 526,000 in Western populations and the incidence is 1 per 250,000 in the US.

Moreover, as the prevalence increases, patients expect more quality treatment for the condition, and this region’s well-established healthcare infrastructure helps in the better management of the condition. Furthermore, North America offers favorable reimbursement policies to the patients for effective treatment and management. The improved insurance coverage offers the better treatment for many patients at affordable costs, leading to market dominance in the region.

Isovaleric Acidemia Market Companies

The major global players in the isovaleric acidemia market include Chengda Pharmaceuticals, Lonza Capsules & Health Ingredients, Zhejiang Bamboo Pharmaceuticals Co., Ltd.., Northeast Pharmaceutical Group Co., Ltd, Liaoning KONCEPNUTRA CO., LTD., Rochem International Inc., Paras Intermediates Private Ltd., Tecoland Corporation, Kyowa Hakko USA Inc., and Penta Manufacturing Company, among others. 

COVID-19 Impact Analysis

The outbreak and onset of the COVID-19 pandemic in late 2019 and 2020, created unprecedented challenges for pharmaceutical industries worldwide, including the global isovaleric acidemia market. During the pandemic, patients with this rare type of disorder are unable to diagnose and detect their condition due to the redirected focus on the COVID-19 pandemic and its related restrictions.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials of isovaleric acidemia such as supplements. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of supplements for the management of the condition due to disruptions in their supply chain networks.

DataM Intelligence Opinion:

According to the DataM Intelligence, the isovaleric acidemia market is a very rare type of disease market. The disease has no treatment but management of the condition helps to prevent the further risks associated with this disease. As there is no cure for this disease, many pharmaceutical companies and research academics are still trying to evolve the treatment options by performing research activities. Moreover, as it is a rare type of disease, there is no specific clinical trials and launches due to their lack of awareness and insufficient funding and investments.

Why Purchase the Report?

• To visualize the global isovaleric acidemia market segmentation based on disease type, supplement type, distribution channel and region as well as understand key commercial assets and players
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of isovaleric acidemia market-level with all segments
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study
• Product mapping available as excel consisting of key products of all the major players

The global isovaleric acidemia market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies